Synergy Innovation is fostering the bio business as a new growth engine. Synergy Innovation intend to become a ‘Bio business management platform' that fosters star companies in the Bio industry field by positively conducting R&D and internal and external investments in various fields such as new drugs, generic drugs, medical devices, and medical materials.
Microscopic organism culture medium business
Synergy Innovation Bio Business Headquarters supplies high-quality raw media and standard strains to most of the hospitals, diagnostic labs, and pharmaceutical companies nationwide. Also, Synergy Innovation produce and supply Microscopic organism culture medium medium that is one of the reagents for in vitro diagnostic analyzers and is widely used for environmental monitoring of pharmaceutical manufacturing environments in a manufacturing environment that has obtained ISO13485 international certification and GMP certification for medical device.
New drug development Business
Three original patents related to gene therapy, which are in the spotlight as next-generation treatments, have been acquired from The Seoul National University R&DB for the development of new drugs Business. Synergy Innovation plans to secure lung cancer treatment using a new DDS, skin cancer treatment using gold nano cells, and breast cancer treatment applicating technology to aggressively use it for future gene therapy development.
About 60 items are exported to 13 countries around the world in accordance with the stability and packaging techniques suitable for the climate and pharmaceutical environment of the partner country, manufactured according to the GMP standards of the MFDS.
Through strategic alliances with domestic and international companies, MedicaKorea is conducting research on IMD as a short & mid term business strategy which shows short development period and high commercialization potential. As the long term business goal, MedicaKorea aims to expand the therapeutic market share through the development of new drugs such as metabolism and cognitive impairment, and grow as a one of the major domestic pharmaceutical companies through the Biopharmaceutical and Nutraceuticals business.
CDMO
CDMO production of items recognized for biological equivalence by the MFDS
Medicine wholesales
Mainly supplies ETCs to hospitals and clinics
Nutraceuticals development & launch
Development and supply own Nutraceuticals brands and products
R&D of regenerative materials for elders
Diversifying regenerative therapy research with medical collagen
- Add(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
- Tel+82-70-4018-8009
- Fax+82-02-3486-2613
- E-mailneuro_reply@neurobiogen.com